The medical community has long sought a way to stop the heart from permanently scarring and reshaping itself after a major heart attack. While traditional treatments manage the symptoms and the hormonal responses of the body, a novel attempt to rewrite the heart’s genetic response has hit a significant roadblock.
In the first major clinical trial of RNA therapy in heart failure, an experimental agent designed to block the proteins that drive adverse cardiac remodeling failed to show a significant benefit over a placebo. The results of the HF-REVERT trial, published in Nature Medicine and presented at the Heart Failure 2026 conference, indicate that the drug did not meaningfully reduce the enlargement of the left ventricle in patients who had recently suffered a myocardial infarction.
Despite the setback, the trial marks a pivotal moment in cardiology. For decades, the standard of care has focused on neurohormonal and hemodynamic pathways—essentially managing the pressure and chemicals affecting the heart. This study was one of the first to test a disease-modifying approach, attempting to target the actual molecular machinery that causes the heart muscle to thicken and stiffen after an injury.
Targeting the Genetic Software of the Heart
The experimental drug, known as CDR132L, was developed by Novo Nordisk and Cardior Pharmaceuticals. It’s a locked nucleic acid-based antisense oligonucleotide, a sophisticated piece of synthetic genetic material designed to inhibit microRNA-132 (miR-132).
In the wake of a heart attack, miR-132 acts as a stress-induced trigger. When this microRNA is overexpressed, it drives “adverse cardiac remodeling”—a process where the heart’s left ventricle changes shape, becomes fibrotic, and loses its ability to pump blood efficiently. By suppressing this specific microRNA, researchers hoped to prevent hypertrophy and fibrosis, thereby helping the heart recover its natural function.
Dr. Thomas Thum, a specialist in internal medicine and cardiology at the Institute of Molecular and Translational Therapeutic Strategies at Hannover Medical School, explained that the goal was to reduce pathological processes such as impaired calcium handling and contractile dysfunction. The ambition was not just to keep the patient stable, but to fundamentally improve the recovery of the left ventricle.
The HF-REVERT Trial: Design and Findings
The study enrolled 294 patients who had recently experienced a myocardial infarction and were suffering from left ventricular (LV) systolic dysfunction. The researchers focused on a modified intention-to-treat population of 280 patients, with a median age of 61 years; approximately 88% of the participants were men, and the median LV ejection fraction was 35.86%.
Patients were randomized to receive either a 5 mg/kg dose of CDR132L, a 10 mg/kg dose, or a placebo. The treatment consisted of three intravenous doses administered at four-week intervals, layered on top of existing guideline-directed medical therapy. The primary objective was to measure the percentage change in the left ventricular end-systolic volume index (LVESVI) over six months.
| Metric | CDR132L (5 mg/kg) vs Placebo | CDR132L (10 mg/kg) vs Placebo | Result |
|---|---|---|---|
| Primary Endpoint (LVESVI Change) | 1.11 percentage points diff. | 2.14 percentage points diff. | Not Significant |
| LVEF (6-month change) | No significant diff. | No significant diff. | Not Significant |
| Safety/Toxicity | Well tolerated | Well tolerated | Safe |
| Target Engagement | Dose-dependent suppression | Dose-dependent suppression | Successful |
The data revealed that the drug did not meet its primary endpoint. There were no statistically significant differences in the LV end-systolic volume index between the treatment groups and the placebo group. Secondary endpoints—including changes in left ventricular ejection fraction (LVEF), global longitudinal strain, and N-terminal pro-B-type natriuretic peptide (NT-proBNP)—showed no meaningful improvement.
However, the trial was not a total failure from a scientific perspective. The drug was well tolerated, with no relevant toxicity signals in the liver, kidneys, or blood. Most importantly, it proved that the drug actually reached its target, showing a dose-dependent suppression of circulating miR-132.
The Pivot to Chronic Heart Failure
While the results for acute post-heart attack patients were disappointing, the researchers believe the drug may still have a role in other stages of the disease. Exploratory analyses suggested that patients with more advanced remodeling—those with higher baseline NT-proBNP or LVESVI—might have derived more benefit from the therapy.
Because of these findings, Novo Nordisk is shifting its focus. The company is not planning further development of CDR132L for the post-acute myocardial infarction population, but it is continuing to investigate the drug’s potential in chronic heart failure. Two Phase 2 clinical proof-of-concept trials are currently underway: 8212-Preserved, targeting heart failure with preserved ejection fraction and LV hypertrophy, and 8282-Reduced, targeting heart failure with reduced or midrange ejection fraction.
The failure of this first attempt at RNA therapy in heart failure highlights the complexity of the heart’s healing process. As Dr. Thum noted, while the agent was biologically active and safe, efficacy must now be demonstrated in the right patient population, with the correct treatment duration and a refined endpoint strategy.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a healthcare provider for diagnosis and treatment of heart failure or cardiac conditions.
The next major checkpoint for CDR132L will be the results of the Phase 2 trials for chronic heart failure, which will determine if RNA-targeted therapy can find a foothold in treating long-term cardiac dysfunction.
Do you think genetic therapies are the future of cardiology, or should we stick to traditional pharmacological management? Share your thoughts in the comments below.
